Need help finding what you are looking for?
Contact Us
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2051214
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 2051214
Influenza Vaccines Market, By Vaccine Type, By Valency, By Route of Administration, By Age Group, By Technology, By Distribution Channel, By Geography
PUBLISHED:
PAGES: 151 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Influenza Vaccines Market is estimated to be valued at USD 9.58 Bn in 2026 and is expected to reach USD 15.89 Bn by 2033, growing at a compound annual growth rate (CAGR) of 7.5% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 9.58 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.50% | 2033 Value Projection: | USD 15.89 Bn |
Influenza vaccines have been an important element of preventive healthcare for decades. The influenza viruses have the ability to mutate and evolve regularly, necessitating the development of updated vaccines each year. The vaccines work to boost the body's immune response to these changing viruses. They are designed to immunize against the three or four strains (depending on the vaccine type used for a particular flu season) that surveillance and other scientific studies have determined are most likely to be in circulation for the upcoming flu season in any given region. The global influenza vaccines market has witnessed steady growth over the past few years due to the growing awareness about seasonal vaccination, introduction of novel technologies, expansion of vaccination guidelines by healthcare organizations, and rising government support worldwide.
Market Dynamics
The global influenza vaccines market growth is driven by various factors such as the increasing prevalence of influenza, growing adoption of vaccination guidelines set by international health organizations, rising awareness about vaccination, new product launches, growing preference for recombinant technology vaccines, and expansion in geographical reach of major players. However, the market growth can be challenging due to high R&D costs involved for development of quadrivalent influenza vaccines, stringent regulatory guidelines for approval of new vaccines and vaccine resistance arising due to antigenic drift of influenza virus strains. The market players see opportunities in emerging countries owing to improving healthcare infrastructure and rising disposable incomes. Manufacturers are also working on the development of universal influenza vaccine with durable protection against multiple flu strains.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global influenza vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen Inc., Moderna Inc., Biocryst Pharmaceuticals Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, Solaris Vaccines, Pfizer, CSL, Daiichi Sankyo, Bharat Biotech, and Sinovac Biotech.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global influenza vaccines market.
Market Segmentation
- Vaccine Type Insights (Revenue, USD Bn, 2026 - 2033)
- Inactivated
- Live Attenuated
- Valency Insights (Revenue, USD Bn, 2026 - 2033)
- Quadrivalent
- Trivalent
- Route of Administration Insights (Revenue, USD Bn, 2026 - 2033)
- Injection
- Nasal Spray
- Age Group Insights (Revenue, USD Bn, 2026 - 2033)
- Pediatrics
- Adults
- Technology Insights (Revenue, USD Bn, 2026 - 2033)
- Egg-Based Flu Vaccines
- Cell Culture-Based Flu Vaccines
- Recombinant Flu Vaccines
- Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
- Public
- Private
- Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen Inc.
- Moderna Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
Product Code: CMI1705
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Valency
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Technology
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Developments
- Industry Trends
- Regulatory Scenario
- Recent Product Approval/Launches
- PEST Analysis
- Porter's Analysis
4. Global Influenza Vaccines Market, By Vaccine Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Inactivated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Live Attenuated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Influenza Vaccines Market, By Valency, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Quadrivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Trivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Influenza Vaccines Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Influenza Vaccines Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Influenza Vaccines Market, By Technology, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Egg-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cell Culture-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Recombinant Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Influenza Vaccines Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Influenza Vaccines Market, By Region, 2021 - 2033 (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033(%)
- Y-o-Y Growth Analysis, For Regions, 2021 - 2033
- Regional Trends
- North America
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033 (USD Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Vaccine Type, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Valency, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Technology, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033 (USD Bn)
- Market Size and Forecast, By Region/Country, 2021 - 2033 (USD Bn)
- South Africa
- Central Africa
- North Africa
11. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- CSL Seqirus
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- FluGen, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Moderna, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biocryst Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CPL Biologicals Pvt. Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CureVac AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- OSIVAX
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Solaris Vaccines
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Daiichi Sankyo
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bharat Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sinovac Biotech
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Solaris Vaccines
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CSL Seqirus
12. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
13. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.